Despite a paucity of clinical trial proof, methotrexate is often advocated or mandated to treat psoriatic arthritis. A recent comparison of clinical trials outcomes fails to show any added value when MTX is given to PsA patients taking etanercept.
Obesity is epidemic in North America, affecting nearly 76 million adults. Obesity is not only a risk factor for rheumatoid arthritis and osteoarthritis, it clearly worsens pain and function in most musculoskeletal (MSK) conditions and has been shown to blunt DMARD and biologic resp
Early referral and diagnosis remains a challenge for many who care for patients with musculoskeletal complaints. This is especially so in those with chronic low back pain (LBP) and the minority who will have ankylosing spondylitis or axial spondyloarthritis.
The Centers for Disease Control and Prevention (CDC) routinely surveys the population prevalence of certain chronic disorders, including arthritis.
Interchangeability is a major issue that will determine the success of biosimilars.
Idiopathic inflammatory myopathies (IIMs) may be complicated with life-threatening conditions requiring intensive care unit (ICU) admission. The outcomes of such complications may be dire, but there are few series addressing the outcomes of those admitted to the ICU.
Silverman and a panel from the IOF Fracture Working Group reviewed the data and trials to develop guidelines for the use of osteoporosis medications after incident fractures or to treat delayed fracture healing.
Doshi and colleagues have conducted a retrospective claims analysis (2009 through 2012) of psoriasis patients on Medicare to examine the use and adherence to those initiating treatment with either infliximab, etanercept, adalimumab, or ustekinumab.
Like other extraarticular manifestations, rheumatoid (RA) or connective tissue disease (CTD) related interstitial lung disease (ILD) is difficult to identify early and equally challenging to treat.
It is important to know where you’ve been, as it will most certainly color where you are going. Hence, in honor of our 1st year anniversary, we have taken note of our most popular articles.
Doctors have an interesting problem. They have an ingrained professional obsessive-compulsive habit; they fixate on the care of individual patients and on the science of healing. This is an admirable trait; it results in high-quality care. However, when physicians need to change their attention from healer to leader, from medicine to the business of medicine, from healthcare to the healthcare system, they falter. Stuck in silos, they fail to adjust their focus. They resist systemic innovation. Because they cannot flip, they flop.
Watch Dr. Jack Cush cover ten highlights from this week on RheumNow.com.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
